Leap Therapeutics' novel GDF-15 neutralizing antibody FL-501 demonstrated superior efficacy in preclinical models, fully restoring body composition and reversing key indicators of cancer cachexia.
Leap Therapeutics' anti-DKK1 antibody sirexatamab shows promising results in colorectal cancer trials while falling short in gastric cancer studies, leading to significant stock impact.
Leap Therapeutics' DeFianCe study showed a 35% objective response rate (ORR) in second-line colorectal cancer (CRC) patients treated with sirexatamab, bevacizumab, and chemotherapy.
Leap Therapeutics completed enrollment in Part B of the Phase 2 DeFianCe study, evaluating DKN-01 with bevacizumab and chemotherapy for second-line advanced colorectal cancer, with data expected mid-2025.
A phase IIa trial of DKN-01 with tislelizumab and chemotherapy demonstrated a 73% objective response rate in advanced gastric or gastroesophageal junction adenocarcinoma.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.